Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Sai Prasad Desikan,Naval Daver,Sanam Loghavi,Tapan M Kadia,Nicholas Short,Courtney D Dinardo,Gautam Borthakur,Sherry A Pierce,Keyur P Patel,Hussein A Abbas,Abhishek Maiti,Guillermo Garcia-Manero,Farhad Ravandi,Hagop Kantarjian,Musa Yilmaz

doi:10.1182/blood-2022-166655

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Sai Prasad Desikan, Naval Daver + Show 13 more

Open Access

https://doi.org/10.1182/blood-2022-166655

Copy DOI

Journal: Blood

Publication Date: Nov 15, 2022

Affiliation: The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Houston

#Internal Tandem Duplications Mutations #Low-intensity Chemotherapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.